Mahana Therapeutics Obtains CE Mark in the UK

Mahana Therapeutics, a digital therapeutics firm, has obtained a CE mark for its flagship product Parallel. Parallel is a prescription-only (PDT) intended to reduce the severity of irritable bowel syndrome (IBS) symptoms in adult patients.

The program was developed in collaboration with expert researchers under the leadership of Professor Rona Moss-Morris, PhD of King’s College, London and Professor Hazel Everitt of the University of Southampton. Parallel has also been recommended for Evaluation in Practice by the National Institute for Health and Care Excellence (NICE).

“We entered into this collaboration with Mahana because of our shared commitment to developing clinically validated, cost-effective treatment options that address IBS symptoms,” said Professor Rona Moss-Morris, Professor of Psychology as Applied to Medicine and Head of Psychology at King’s College, London, who led the development of the initial Parallel program.

“I am excited and proud that the result of our work together has met the high health and safety standards needed to obtain a CE mark,” she stressed.

In the UK, IBS affects up a large percentage of the UK. More than half of IBS patients don’t feel that their prescription drugs alone provide effective relief from IBS.

Those suffering from IBS often experience a range of symptoms, both physical and psychological. Parallel is intended to be used in conjunction with other IBS treatments to reduce the severity of these symptoms.

Steven Basta, Mahana CEO, said: “Mahana was founded with the needs of patients at its heart. Earning a CE mark certification represents an exciting new phase for our work to deliver innovative treatment options to patients struggling with IBS symptoms.”

Professor Hazel Everitt, GP and professor of primary care research, Faculty of Medicine, University of Southampton, said: “I see many patients in my clinical practice who continue to struggle with ongoing IBS symptoms despite trying medications. This led me to undertake research to provide rigorous evidence for new options. Randomized controlled trials, including the one I led, have shown that CBT designed specifically for IBS can meaningfully reduce the severity of IBS symptoms.”